Advertisement

American Diabetes Association, June 10-14

0
The American Diabetes Association's 76th Scientific Sessions The annual meeting of the American Diabetes Association was held from June 10 to 14 in...
For patients with type 2 diabetes

Even Short-Term T2DM Remission Reduces Risk of Microvascular Dz

0
Length of time spent in remission inversely related to risk of microvascular disease
The Diabetes Collaborative Registry provides information regarding the quality of diabetes mellitus care

ADA: Diabetes Collaborative Registry IDs Burden of Cardiac Risk

0
Registry offers information on quality of diabetes care across primary, specialty care spectrum
For patients with type 2 diabetes at high cardiovascular risk

ADA: Empagliflozin Linked to Reduction in T2DM Nephropathy

0
Reduction in incident or worsening nephropathy, and in doubling of serum creatinine level
Helicobacter pylori infection is associated with metabolic syndrome

Review Links H. pylori Infection With Metabolic Syndrome

0
Infection also linked to higher triglycerides, fasting blood glucose, BMI, HOMA-IR, systolic BP, lower HDL
Intensive blood glucose control appears to reduce the risk of retinopathy progression in patients with type 2 diabetes

Intensive HbA1c Control Cuts Diabetic Retinopathy Progression

0
Patients with type 2 diabetes reduced their risk by half with intensive management
American seniors with diabetes are starting to live longer without disabilities

American Seniors With Diabetes Living Longer Without Disability

0
Researchers find increase in 'good' years of life in recent decades
Genetic variants in CYP2C8 and SLCO1B1 impact the therapeutic response to rosiglitazone in patients with type 2 diabetes

CYP2C8, SLCO1B1 Variants Impact Response to Rosiglitazone

0
Genetic variants have clinical impact on response to rosiglitazone, but not pioglitazone
For females with Crohn's disease

Oral Contraceptive Use Ups Surgery Risk in Crohn’s

0
Long-term use of oral contraceptives, especially combination type, linked to increased surgery risk
Compared with bevacizumab

Aflibercept, Ranibizumab Not Cost-Effective Vs. Bevacizumab

0
Not cost-effective for diabetic macular edema unless prices decrease considerably